Your browser doesn't support javascript.
loading
Plasma miRNA, an emerging biomarker for pancreatic cancer.
Yu, Xiazhen; Koenig, Michelle R; Zhu, Yuwen.
Afiliação
  • Yu X; 1 Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA ; 2 Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University, Hangzhou 310009, China.
  • Koenig MR; 1 Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA ; 2 Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University, Hangzhou 310009, China.
  • Zhu Y; 1 Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA ; 2 Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University, Hangzhou 310009, China.
Ann Transl Med ; 3(19): 297, 2015 Nov.
Article em En | MEDLINE | ID: mdl-26697457
Pancreatic cancer (PC) is one of the most dangerous types of cancer, much due to the lack of clinical symptoms in early stages. Early, noninvasive methods of detecting PC remain a great challenge in clinical practices. MicroRNAs (miRNAs), small and non-coding single-strand RNAs, emerge as potential biomarkers for PC. MiRNAs are involved in PC progression and abnormal level of miRNAs in plasma has been observed in PC patients. A multi-center study recently conducted by Xu and colleagues demonstrated the potential value of using circulating miRNAs to distinguish PC from normal donors and other pancreas-related diseases.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article